SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
March, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
|
Description of Exhibits |
|
|
|
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) |
||
|
|
||
Date: March 10, 2026 |
By: |
/s/ K Randhir Singh |
|
|
|
Name: K Randhir Singh |
|
|
|
Title: Company Secretary |
|
| 3 |
Exhibit 99.1
|
|
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
March 10, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: |
Disclosure pursuant to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – News article with the heading “Delhi High Court allows Dr Reddy's to make Semaglutide for export” |
This is in reference to a news article published on March 10, 2026, including the article in Business Standard titled “Delhi High Court allows Dr Reddy's to make Semaglutide for export” (https://www.business-standard.com/india-news/delhi-hc-allows-dr-reddys-to-manufacture-semaglutide-for-export-126030900996_1.html). Similar reports have also appeared in other mainstream media..
In this regard, the Company hereby clarify that the said news pertains to an ongoing interim injunction proceeding between the Company and Novo Nordisk, a Danish drug maker, involving Semaglutide containing products. The Division Bench of Delhi High Court, through its judgment dated March 09, 2026, has upheld the previous Single-Judge Bench’s order that permitted the Company to manufacture Semaglutide in India and export to other countries where Novo Nordisk does not hold a patent registration, refusing to grant an interim injunction on Semaglutide containing products.
We would further like to inform that the matter remains sub-judice and at this stage there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR